secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001683168-25-006042
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort
--------------------------------------------------------------------------------

- Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.
- First cohort completed in Australian Hemopurifier cancer trial; DSMB approves second cohort with two treatments.
- Amended protocol broadens eligibility to any anti-PD-1 regimen; preclinical data show 98.5% removal of platelet-derived EVs.
- India oncology study dropped due to extended timeline; Long COVID research with UCSF presented at Keystone Symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/0001683168-25-006042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316825006042/aemd_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-006042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer